KR102864285B1 - 트라디피탄트를 이용한 위장 질환의 치료 방법 - Google Patents

트라디피탄트를 이용한 위장 질환의 치료 방법

Info

Publication number
KR102864285B1
KR102864285B1 KR1020207014967A KR20207014967A KR102864285B1 KR 102864285 B1 KR102864285 B1 KR 102864285B1 KR 1020207014967 A KR1020207014967 A KR 1020207014967A KR 20207014967 A KR20207014967 A KR 20207014967A KR 102864285 B1 KR102864285 B1 KR 102864285B1
Authority
KR
South Korea
Prior art keywords
tradipitant
pharmaceutical composition
day
gastroparesis
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207014967A
Other languages
English (en)
Korean (ko)
Other versions
KR20200088346A (ko
Inventor
미하엘 에이치. 폴리머로풀로스
군터 버즈니엑스
Original Assignee
반다 파마슈티칼즈, 인코퍼레이티드.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 반다 파마슈티칼즈, 인코퍼레이티드. filed Critical 반다 파마슈티칼즈, 인코퍼레이티드.
Priority to KR1020257031352A priority Critical patent/KR20250140655A/ko
Publication of KR20200088346A publication Critical patent/KR20200088346A/ko
Application granted granted Critical
Publication of KR102864285B1 publication Critical patent/KR102864285B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207014967A 2017-11-17 2018-11-16 트라디피탄트를 이용한 위장 질환의 치료 방법 Active KR102864285B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257031352A KR20250140655A (ko) 2017-11-17 2018-11-16 트라디피탄트를 이용한 위장 질환의 치료 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762587681P 2017-11-17 2017-11-17
US62/587,681 2017-11-17
PCT/US2018/061593 WO2019099883A1 (en) 2017-11-17 2018-11-16 Method of treatment of gastrointestinal diseases with tradipitant

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257031352A Division KR20250140655A (ko) 2017-11-17 2018-11-16 트라디피탄트를 이용한 위장 질환의 치료 방법

Publications (2)

Publication Number Publication Date
KR20200088346A KR20200088346A (ko) 2020-07-22
KR102864285B1 true KR102864285B1 (ko) 2025-09-24

Family

ID=64734107

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207014967A Active KR102864285B1 (ko) 2017-11-17 2018-11-16 트라디피탄트를 이용한 위장 질환의 치료 방법
KR1020257031352A Pending KR20250140655A (ko) 2017-11-17 2018-11-16 트라디피탄트를 이용한 위장 질환의 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257031352A Pending KR20250140655A (ko) 2017-11-17 2018-11-16 트라디피탄트를 이용한 위장 질환의 치료 방법

Country Status (19)

Country Link
US (4) US20200030307A1 (enExample)
EP (1) EP3710000B1 (enExample)
JP (1) JP7306614B2 (enExample)
KR (2) KR102864285B1 (enExample)
CN (2) CN119074729A (enExample)
AU (1) AU2018367623B2 (enExample)
BR (1) BR112020009520A2 (enExample)
CA (1) CA3081582A1 (enExample)
CL (1) CL2020001290A1 (enExample)
DK (1) DK3710000T3 (enExample)
ES (1) ES3032138T3 (enExample)
FI (1) FI3710000T3 (enExample)
HR (1) HRP20250615T1 (enExample)
HU (1) HUE071527T2 (enExample)
IL (1) IL274541B2 (enExample)
MX (1) MX2020005167A (enExample)
PT (1) PT3710000T (enExample)
SI (1) SI3710000T1 (enExample)
WO (1) WO2019099883A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US20210228555A1 (en) * 2018-06-08 2021-07-29 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
CN111918701B (zh) * 2018-09-28 2024-08-02 万达制药公司 曲地匹坦在晕动病中的用途
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP7791832B2 (ja) 2020-03-26 2025-12-24 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる下気道感染症の治療
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
JP2025542424A (ja) 2022-12-21 2025-12-25 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによる処置の方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003230829B8 (en) 2002-04-26 2008-12-11 Eli Lilly And Company Triazole derivatives as tachykinin receptor antagonists
KR100848407B1 (ko) * 2003-10-24 2008-07-28 일라이 릴리 앤드 캄파니 ｛2-[1-(3,5-비스-트리플루오로메틸벤질)-5-피리딘-4-일-1ｈ-[1,2,3]트리아졸-4-일]-피리딘-3-일｝-(2-클로로페닐)-메탄온의 신규 결정질 형태
WO2008079600A1 (en) * 2006-12-20 2008-07-03 Eli Lilly And Company Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
HRP20140759T1 (hr) * 2009-11-18 2014-10-24 Helsinn Healthcare S.A. Kompozicije za lijeäśenje središnje posredovane muäśnine i povraä†anja
WO2016141341A1 (en) * 2015-03-04 2016-09-09 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
CA3009325A1 (en) 2015-12-22 2017-06-29 Takeda Pharmaceutical Company Limited Tripartite modulators of endosomal g protein-coupled receptors

Also Published As

Publication number Publication date
JP2021503480A (ja) 2021-02-12
US20210330656A1 (en) 2021-10-28
AU2018367623A1 (en) 2020-05-21
US20200030307A1 (en) 2020-01-30
NZ764107A (en) 2024-07-05
EP3710000B1 (en) 2025-04-23
CN111343981A (zh) 2020-06-26
IL274541B1 (en) 2024-06-01
US20210093621A1 (en) 2021-04-01
SI3710000T1 (sl) 2025-07-31
KR20200088346A (ko) 2020-07-22
WO2019099883A1 (en) 2019-05-23
PT3710000T (pt) 2025-05-29
FI3710000T3 (fi) 2025-07-03
RU2020119259A (ru) 2021-12-17
AU2018367623B2 (en) 2024-03-28
CN119074729A (zh) 2024-12-06
CL2020001290A1 (es) 2020-11-13
IL274541B2 (en) 2024-10-01
EP3710000A1 (en) 2020-09-23
JP7306614B2 (ja) 2023-07-11
KR20250140655A (ko) 2025-09-25
BR112020009520A2 (pt) 2020-11-03
HUE071527T2 (hu) 2025-09-28
MX2020005167A (es) 2020-08-20
HRP20250615T1 (hr) 2025-07-18
US20230390269A1 (en) 2023-12-07
DK3710000T3 (da) 2025-06-16
ES3032138T3 (en) 2025-07-15
IL274541A (en) 2020-06-30
CA3081582A1 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
KR102864285B1 (ko) 트라디피탄트를 이용한 위장 질환의 치료 방법
US20220096449A1 (en) Method of treatment with tradipitant
US20240285588A1 (en) Use of tradipitant in motion sickness
Kobayashi et al. Effects of YM905, a novel muscarinic M3-receptor antagonist, on experimental models of bowel dysfunction in vivo
JP2001502311A (ja) 抗鬱及び／又は抗不安薬としてのｃｎｓ浸透性ｎｋ―１受容体拮抗薬
US20210008037A1 (en) Use of tradipitant in motion sickness
Watanabe et al. Pharmacological Characterization of T-2328, 2-Fluoro-4’-methoxy-3’-[[[(2S, 3S)-2-phenyl-3-piperidinyl] amino] methyl]-[1, 1’-biphenyl]-4-carbonitrile Dihydrochloride, as a Brain-Penetrating Antagonist of Tachykinin NK1Receptor
RU2797248C2 (ru) Способ лечения заболеваний желудочно-кишечного тракта традипитантом
US20240299373A1 (en) Improved use of tradipitant in motion sickness
US11752141B2 (en) Pharmaceutical compositions and methods utilizing neostigmine and an NK-1 antagonist for treating myasthenia gravis
NZ766397B2 (en) Use of tradipitant in motion sickness

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A18-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)